192 related articles for article (PubMed ID: 36593473)
21. EQ-5D-Y Value Set for Germany.
Kreimeier S; Mott D; Ludwig K; Greiner W;
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
[TBL] [Abstract][Full Text] [Related]
22. New methods for modelling EQ-5D-5L value sets: An application to English data.
Feng Y; Devlin NJ; Shah KK; Mulhern B; van Hout B
Health Econ; 2018 Jan; 27(1):23-38. PubMed ID: 28833854
[TBL] [Abstract][Full Text] [Related]
23. How different are composite and traditional TTO valuations of severe EQ-5D-5L states?
Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA
Qual Life Res; 2016 Aug; 25(8):2101-8. PubMed ID: 26875190
[TBL] [Abstract][Full Text] [Related]
24. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
25. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
[TBL] [Abstract][Full Text] [Related]
26. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
27. A direct comparison between discrete choice with duration and composite time trade-off methods: do they produce similar results?
Roudijk B; Jonker MF; Bailey H; Pullenayegum E
Value Health; 2024 Jun; ():. PubMed ID: 38843979
[TBL] [Abstract][Full Text] [Related]
28. Cross-Attribute Level Effects Models for Modeling Modified 5-Level Version of EQ-5D Health State Values: Is Less Still More?
Yang Z; Rand K; Busschbach J; Luo N
Value Health; 2023 Jun; 26(6):865-872. PubMed ID: 36566885
[TBL] [Abstract][Full Text] [Related]
29. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
[TBL] [Abstract][Full Text] [Related]
30. Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.
Stolk E; Ludwig K; Rand K; van Hout B; Ramos-Goñi JM
Value Health; 2019 Jan; 22(1):23-30. PubMed ID: 30661630
[TBL] [Abstract][Full Text] [Related]
31. Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data.
Ramos-Goñi JM; Oppe M; Estévez-Carrillo A; Rivero-Arias O;
Value Health; 2022 May; 25(5):835-843. PubMed ID: 35500952
[TBL] [Abstract][Full Text] [Related]
32. An Exploration on Attribute Non-attendance Using Discrete Choice Experiment Data from the Irish EQ-5D-5L National Valuation Study.
Doherty E; Hobbins A; Whitehurst DGT; O'Neill C
Pharmacoecon Open; 2021 Jun; 5(2):237-244. PubMed ID: 33481204
[TBL] [Abstract][Full Text] [Related]
33. A national survey of Iranian general population to estimate a value set for the EQ-5D-5L.
Afshari S; Daroudi R; Goudarzi R; Mahboub-Ahari A; Yaseri M; Sari AA; Ameri H; Bahariniya S; Oliaei-Manesh A; Kalavani K; Zare Z; Hasannezhad E; Mirzaei M; Amiri Z
Qual Life Res; 2023 Jul; 32(7):2079-2087. PubMed ID: 36897530
[TBL] [Abstract][Full Text] [Related]
34. The EQ-5D-5L valuation study in Korea.
Kim SH; Ahn J; Ock M; Shin S; Park J; Luo N; Jo MW
Qual Life Res; 2016 Jul; 25(7):1845-52. PubMed ID: 26961008
[TBL] [Abstract][Full Text] [Related]
35. Investigating the relative value of health and social care related quality of life using a discrete choice experiment.
Mulhern B; Norman R; De Abreu Lourenco R; Malley J; Street D; Viney R
Soc Sci Med; 2019 Jul; 233():28-37. PubMed ID: 31153085
[TBL] [Abstract][Full Text] [Related]
36. An EQ-5D-5L Value Set for Belgium.
Bouckaert N; Cleemput I; Devriese S; Gerkens S
Pharmacoecon Open; 2022 Nov; 6(6):823-836. PubMed ID: 35927410
[TBL] [Abstract][Full Text] [Related]
37. The EQ-5D-5L Valuation study in Thailand.
Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
[TBL] [Abstract][Full Text] [Related]
38. Public versus patient health preferences: protocol for a study to elicit EQ-5D-5L health state valuations for patients who have survived a stay in intensive care.
Halling CMB; Gudex C; Perner A; Jensen CE; Gyrd-Hansen D
BMJ Open; 2022 May; 12(5):e058500. PubMed ID: 35613809
[TBL] [Abstract][Full Text] [Related]
39. Valuing EQ-5D-5L health states 'in context' using a discrete choice experiment.
Cole A; Shah K; Mulhern B; Feng Y; Devlin N
Eur J Health Econ; 2018 May; 19(4):595-605. PubMed ID: 28569351
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
